Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
127 hedge funds and large institutions have $415M invested in Achillion Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 41 increasing their positions, 38 reducing their positions, and 36 closing their positions.
1,106% more call options, than puts
Call options by funds: $3.12M | Put options by funds: $259K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
27% more capital invested
Capital invested by funds: $327M → $415M (+$88.7M)
8% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 38
15% less funds holding
Funds holding: 149 → 127 (-22)
53% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$15.2M |
| 2 |
AC
Armistice Capital
New York
|
+$14.1M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12.1M |
| 4 |
Goldman Sachs
New York
|
+$8.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$23.5M |
| 2 |
Morgan Stanley
New York
|
-$14.7M |
| 3 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$6.55M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$4.63M |
| 5 |
Renaissance Technologies
New York
|
-$4.28M |
ACHN Hedge Fund Activity: Q1 2018 in Review
127 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q1 2018, worth a combined $415M — up 27% from $327M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of ACHN and 17 opened new positions — a net loss of 19 holders — while 38 trimmed existing stakes and 41 added.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $15.2M. The largest seller was OrbiMed, exiting entirely with an estimated $23.5M sold.
- 127 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q1 2018, down from 149 in Q4 2017.
- Funds reported $415M of Achillion Pharmaceuticals stock for Q1 2018, up 27% quarter-over-quarter.
- 17 funds opened new Achillion Pharmaceuticals positions in Q1 2018 and 36 closed out, a net change of -19 holders.
- The largest Achillion Pharmaceuticals buyer in Q1 2018 was T. Rowe Price Associates, an estimated $15.2M added.
- The largest Achillion Pharmaceuticals seller in Q1 2018 was OrbiMed, an estimated $23.5M sold.
Based on aggregated 13F filings for Q1 2018.